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ABSTRACT
Varicella-zoster virus gene 62 encodes a protein with
predicted Mr of 140,000D (VZV 140k) that shares
extensive predicted amlno add sequence homology
with the major Immediate early (IE) transcrlptlonal
regulator protein of herpes simplex virus type 1 (HSV-1)
Vmw175. The integrity of highly conserved region 2 is
essential for the DNA binding and transcrlptlonal
regulatory functions of Vmw175. Similarly, an Insertion
mutation in region 2 (codons 468-641) of 140k
eliminates the transcrlptlonal repression and activation
functions of this protein. We have expressed a
fragment of 140k which encompasses region 2 as a
non-fusion polypeptlde in bacteria. This 140k DNA
binding domain peptlde (codons 417-646) binds to
numerous DNA sequences throughout the VZV gene
62 promoter region. It induces multiple regions of
protection from DNase I digestion, flanked by sites of
DNase I hypersensltivity. Several of the sites
recognized can be considered to be divergent forms
of the consensus sequence which is recognized by
Vmw175. However, by use of a panel of mutagenlzed
probe fragments, we found that the 140k DNA binding
domain was less sequence-specific than Vmw175 In Its
Interactions with DNA. Consistent with this, the
homologous Vmw175 DNA binding domain, and also
Intact Vmw175, recognize the gene 62 binding sites
much less efficiently than the 140k DNA binding
domain. Also In contrast to the situation with Vmw175,
the140k DNA binding domain failed to induce DNA
bending when occupying the binding sites In its own
promoter. Deletion analysis has mapped the minimal
DNA binding domain of the VZV 140k protein, as
measured in gel retardation analysis, to lie within
residues 472 to 633. The differences in binding
characteristics of the DNA binding domains of the
homologous VZV 140k and HSV-1 Vmw175 IE proteins
may account for the subtle differences In their
regulatory activities in transfection assays and during
virus growth In tissue culture.
INTRODUCTION
Expression of many herpesvirus genes is coordinately regulated
and sequentially ordered in a cascade fashion. Gene regulation
during herpes simplex type 1 (HSV-1) infection in tissue culture
has been most extensively analyzed. HSV-1 genes are classified
as immediate-early (IE), early or late, depending on their kinetics
of expression and response to inhibitors of macromolecular
synthesis (1,2). The five IE genes are transcribed at the onset
of infection in the absence of de-novo protein synthesis and at
least some of the IE polypeptides are required for the normal
regulation of the later classes of genes (for reviews see 3—5).
Of the five IE gene products, Vmwl75 (expressed from gene
IE-3) is perhaps the most important since its inactivation results
in failure to transcribe early and late genes and an apparent over-
expression of the IE genes (6,7). Thus Vmwl75 is directly or
indirectly required for the normal expression of all other HSV-1
genes.
Varicella-zoster virus (VZV), another member of the
neurotropic alphaherpesvirinae subfamily, is genetically closely
related to HSV-1 (8,9). However, in contrast to HSV-1, the
knowledge of gene regulation during VZV infection is still
rudimentary. The major reason for this is the poor growth of
VZV in the available tissue culture systems which produce
predominantly cell associated virus with low titer stocks. Four
VZV IE products have been detected in infected cells by
cycloheximide reversal experiments (10). The gene product of
VZV genes 62 and 71 (the identical gene is present in both copies
of the short repeat regions (Figure 1A)) has a predicted Mr of
140.000D (VZV 140k) and shares considerable predicted amino
acid identity with HSV-1 Vmwl75. For several reasons 140k
is believed to be the functional counterpart of Vmwl75; HSV-1
mutants with lesions in Vmwl75 can be complemented by either
transfected plasmids or transformed cell lines which express VZV
140k (11,12) and moreover a recombinant HSV-1 virus
(HSV-140) with both copies of the Vmwl75 coding sequences
replaced by the homologous gene 71 ORF is viable in tissue
culture (13).
In transfection assays at least, the VZV 140k protein functions
as a powerful transcriptional activator of viral and selected cellular
gene expression (14-16) and autoregulates its own gene 62
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promoter (17). The predicted primary sequence of 140k can be
divided into five regions on the basis of similarity to the
corresponding Vmwl75 protein (18). The integrity of highly
conserved region 2 is required for the transactivation and
repression phenotypes of Vmwl75 (19,20) and an insertion
mutation in 140k region 2 inhibits these same functions (17)
suggesting that VZV 140k and HSV-1 Vmwl75 regulate gene
expression by related mechanisms. However the two proteins are
not entirely interchangeable for autoregulation as Vmwl75 can
substitute for 140k in the downregulation of the VZV gene 62
promoter in transient transfection assays whereas the 140k protein
does not repress the HSV-1 IE-3 promoter in the reciprocal
experiment (17).
In the case of Vmwl75, its autoregulatory function is mediated
at least in part by the formation of a complex between Vmwl75
and a specific sequence fitting the Vmwl75 binding consensus
ATCGTnnnnnYSG (21,22 and references therein) found at the
cap site of the IE-3 promoter (23). This complex is presumed
to downregulate transcription either by sterically blocking the
movement of RNA polymerase II or by displacing an essential
transcriptional factor such as TF11D. The DNA binding domain
of Vmwl75 has been mapped by a variety of different techniques
to a region encompassing the C-terminal protion of region 1 and
the whole of region 2 (19,20,24,25). This domain of Vmwl75
has been expressed as a stable, functionally separable domain
in bacteria (25,21), exists as a dimer in solution (21) and binds
DNA with a specificity similar to that of the intact protein (25,21).
Both intact Vmwl75 and its isolated DNA binding domain bend
DNA when occupying the IE-3 promoter binding site (26). The
biological significance of this DNA bending is unclear but it may
be relevant to the mechanism of autoregulation by Vmwl75.
The corresponding DNA binding domain of VZV 140k has
been expressed as a trpE fusion polypeptide in bacteria
(encompassing codons 417 to 647) (27) and binds to sequences
in the vicinities of both cap sites proposed for its own gene 62
promoter (28,12). Degenerate versions of the HSV-1 Vmwl75
binding consensus are contained within these recognized
sequences. In addition, the same group demonstrated that the
DNA binding domain fusion polypeptide of the homologous
IE 180 protein of pseudorabies virus (PRV) interacted with its
promoter in a similar manner (27). These findings suggest that
the formation of a specific complex between an EE protein and
its own gene promoter may be a common mechanism used by
alphaherpesvirinae to autoregulate transcription of an essential
IE gene.
We sought to investigate whether differences in the behaviour
of 140k and Vmwl75 in autoregulation assays could be explained
by variations in their DNA binding specificities. We have
expressed the region 2 domain of 140k as a non-fusion protein
in E.coli (codons 417 to 646) and analyzed its activities in DNA
binding experiments in comparison with the corresponding
Vmwl75 DNA binding domain. Our results confirm those of
Wu and Wilcox (27) and extend them to identify in more detail
the sites that are bound by the VZV 140k DNA binding domain.
A mutational analysis indicated that the VZV 140k DNA binding
domain was less specific in its DNA binding requirements than
that of Vmwl75, and failed to bend DNA at its binding sites.
These differences in DNA binding properties may be relevant
to the slight differences in their biological properties. In addition,
we have defined the limits of the VZV 140k DNA binding domain
to residues 472—633 using a deletion analysis. This is
significantly smaller than the minimal DNA binding domain of
HSV-1 Vmwl75 (21,25).
MATERIALS AND METHODS
Plasmids, bacteria and bacteriophage
Plasmid pV17 is a derivative of pi40 (a plasmid including the
entire VZV gene 62, see ref 28) with a 12 bp EcoRI linker
oligonucleotide inserted at codon 418. Plasmid p585T7a was
derived from the T7 expression vector p585.4 (21) by removal
of the EcoRI site (by cutting, Klenow fUling-in of 5' overhangs
followed by religation) prior to co-ligation of an NcoI-EcoRI
adaptor oligonucleotide (21) and the EcoRI-Hindm multiple
cloning region (mcr) fragment of PUC19 between the Ncol and
Hindm sites of p585.4 at the initiation of translation. In addition,
the Sphl-PvuH fragment of the vector was removed by cutting
with SphI and PvuTI, Klenow end-filling, followed by blunt-end
ligation, to increase the number of restriction enzyme sites
available for cloning in the p585T7a vector. All plasmids were
constructed and maintained in E.coli strain AH5. For the
expression experiments, plasmids were transformed into E.coli
strain BL21 (DE3) pLysS (29).
Bacteriophage M13 containing wild type and mutant forms of
the HSV-1 IE-3 cap site region (21) were transfected into E.coli
strain JM101. The JM101 host bacterium was used for all
subsequent growth and maintenance of M13 bacteriophage.
Preparation of intact Vmwl75 protein
Crude nuclear extracts containing HSV-1 Vmwl75 protein were
prepared from HeLa cells transfected with the plasmid pi75 as
previously described (30).
Construction of the 140k DNA binding domain expression
plasmids
Plasmid p585T7aVT2 was constructed by cutting the plasmid
pV17 with BstEH, filling-in of the 5' overhang with Klenow,
before cutting again with EcoRI. The resulting EcoRI-BstEII
fragment (containing the 140k codons 417 to 646) was isolated
and inserted between the adaptor EcoRI site and the Smal site
of the vector p585T7a. The NcoI-EcoRI adaptor oligonucleotides
had been synthesized so as to maintain the 140k peptide reading
frame (which is initiated at the ATG of the Ncol site). BamHI
digestion, followed by isolation and religation of the plasmid
construct removed DNA sequences between the BamHI site of
the mcr and the BamHI she in the translational termination region.
The sequences at the 5' and 3' ends of the insertion were
confirmed by direct plasmid sequencing. Plasmid p585T7aVT2
encodes a 257 residue peptide, designated VT2, consisting of
4 amino acids derived from the amino-terminal junction region
sequence (MAEF); the VZV 140k residues 417 to 646; 3 residues
from the mcr (QGI) to its carboxy-terminal side; followed by
20 residues encoded by vector DNA 3' to the BamHI site.
Plasmid p585T7aVT2X was derived from p585T7aVT2 by
insertion of an Xbal linker oligonucleotide containing stop codons
in all three reading frames into the BamHI site of
p585T7aVT2—this removed 19 vector encoded residues from
the distal end of the expressed protein that are present in the VT2
polypeptide. The 238 residue expression product of plasmid
p585T7aVT2X is designated VT2X.
Plasmids expressing 140k DNA binding domain deletion
polypeptides were constructed using appropriate restriction
enzyme sites (as indicated in Figure 8A) for cloning into the mcr
of plasmid p585T7a. The cloning proceedures ensured that all
constructs were in frame with the ATG translation initiation codon
of the vector. The predicted 5' and 3' boundaries of the expression
regions were confirmed by direct plasmid DNA sequencing.
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Expression and partial purification of the 140k DNA binding
domains
T7 expression plasmids were transformed into E. coli host strain
BL21 (DE3) pLysS and maintained as glycerol stocks. Bacterial
colonies from freshly streaked plates containing ampicillin at
100/ig/ml and chloramphenicol at 25/tg/ml were innoculated into
YT-broth containing the above concentrations of antibiotics, and
grown shaking at 37°C until the OD4J0 was 0.5. IPTG was then
added to a final concentration of 0. lmM and induction followed
at 26°C for a further 2 hours. Bacteria were harvested by
centrifugation and resuspended in 1% culture volume of
resuspension buffer (50mM Hepes pH 7.2, lOOmM NaCl, 6mM
CHAPS, lmM PMSF and 0. lmM DTT) and frozen at -20°C.
Thawed bacteria were disrupted by sonication for 4x 10 sees,
at 80-90 W (using a Dawe soniprobe Type7532A) on ice prior
to addition of DNase I (to 24/tg/ml); RNase A (to 100/tg/ml)
and MgCl2 (to 6mM). After 30 mins incubation at 4°C, NaCl
was added to 1M final concentration followed by addition of
polymin P to 0.2%. The resulting suspensions were centrifuged
at 15K for 15 mins. in me Sorvall SS34 rotor. Supernatants were
made up to 35% saturation with ammonium sulphate and the
precipitated protein pellets dissolved in 0.2% original culture
volume of resuspension buffer. These solutions were clarified
by centrifugation and the supernatants containing the partially
purified extracts stored at —20°C. A partially purified extract
of the HSV-1 Vmwl75 DNA binding domain peptide I9X (31)
prepared by this method was kindly provided by K. E. Allen.
Polyacrylamide gel analysis of expressed proteins
E.coli BL21 bacterial extracts containing the induced viral
proteins were analyzed by electrophoresis through a 12.5% SDS
polyacrylamide gel using the Biorad miniprotean II kit and
visualized by staining with Coomassie blue.
Preparation of probes for DNA binding analyses
End-labelled restriction fragment probes used for DNA binding
analyses on the HSV-1 EE-3 promoter and the VZV gene 62
promoter regions were prepared as follows:- The UP6 probe,
including the gene 62 mRNA start site at nucleotide -287
proposed by Felser (12) was isolated as a Sall-Rsal fragment,
spanning nucleotides -409 to -188 of the gene 62 promoter,
from the plasmid pl40 (28). The BT probe, spanning the mRNA
start site at nucleotide +1 located experimentally by McKee (28)
was isolated as a Xhol-Bgin fragment encompassing residues
-130 to +57 of the gene 62 promoter from the plasmid pl40BT,
a derivative of pl40 with a BglH site inserted at nucleotide +57
(28). The IE-3 probes contained a strong Vmwl75 binding site
(23) located at the cap site of the HSV-1 IE-3 gene and were
isolated as either an Aval-BamHI fragment (coordinates - 1 8 to
+27) or as an EcoRI-BamHI fragment (coordinates -108 to
+27) from the plasmid pIE-3CAT (20). The probes were
constructed by initially cutting the plasmids with either Sail, Xhol
or BamHI respectively, end-labelling with Klenow and a32?
dATP, followed by digestion with the second enzyme as
appropriate. The labelled fragments were eluted from acrylamide
gels and purified by ethanol precipitation. A specific
oligonucleotide probe (UP6 oligo) was synthesized corresponding
to the region of the gene 62 promoter spanning the proposed
mRNA start site at -287, by annealing complementary single
stranded 35mer oligonucleotides carrying sequences derived from
-311 to -283 of the gene 62 promoter flanked by non-gene
62 sequences giving rise to 5' Aval and 3' BamHI sticky ends.
Klenow end-filling, in the presence of a32P dATP yielded the
end-labelled UP6 oligo probe.
Comparative gel retardation analysis of the IE-3 consensus
binding site containing single point mutations used probes
prepared by the 'prime cut' method (32) taking measures to obtain
sets of probes of equal specific activity. In each series of probe
preparations, a wild type control was prepared in an identical
manner at the same time.
DNA bending analysis of the gene 62 promoter sites used
derivatives of the plasmid pBEND2 (33) which includes a
tandemly repeated sequence (containing 17 different restriction
sites) with unique Xbal and Sail cloning sites between the two
repeats. Plasmids pBENDU and pBENDP were constructed by
insertion of the gene 62 promoter UP6 oligo (including gene 62
bases -311 to -283) and an Rsal-Rsal gene 62 promoter
fragment (-23 to +50) respectively into the Sail site of pBEND2
by blunt end ligation following Klenow end-filling of any 5'
overhangs. The direct repeats in these pBEND plasmids, contain
amongst others, BglTI, Xhol and BamHI sites; cutting with any
of these enzymes produced DNA fragments of 184 bp from
pBENDU and 218 bp from pBENDP. These fragments were
Klenow end-labelled and isolated as before to produce two groups
of three probes with 140k binding sites in circularly permuted
positions with respect to their ends.
Gel retardation assays
Appropriate amounts of partially purified DNA binding domain
peptides or nuclear extracts were incubated on ice with O.lng
of end-labelled DNA fragment probes or freshly made 'prime
cut' probes in buffer giving final concentrations of lOmM
Tris.HCl pH8.0, lmM EDTA, lOOmM NaCl, 1/tg
polydl.polydC, 0.1 % NP40 and 50/xg/ml BSA. After incubation
for 20 mins, 0.2 volumes of loading buffer (lOmM Tris.HCl
pH8.0, lmM EDTA, lOmM mercaptoethanol, 0.1% CHAPS,
50% glycerol and 0.25mg/ml bromophenol blue) was added to
each incubation mix. Samples were applied to a non-denaturing
4% polyacrylamide gel with 0.5XTBE running buffer and run
at 150V at 4°C for 3 hrs. Complexes and unbound probe were
detected by autoradiography of dried gels. Where appropriate,
the extent of binding was determined by scintillation counting
of dried gel slices corresponding to the positions of free and bound
probe previously located by autoradiography. To allow for
background values contributed by complexes with E.coli proteins
(which were visually undetectable), dried gel slices from control
lanes were also cut out and counted. These values, which were
negligable, were subtracted from the sample counts, to allow
calculation of the percentage of total probe bound.
DNase I footprinting assays
Site specific protection of DNA fragments from partial DNase
I digestion by the 140k VT2 and Vmwl75 I9X DNA binding
domain peptides was determined by modification of the method
of Galas and Schmitz (34). DNA binding reactions contained 4ng
of target DNA labelled with ^P at one 5' end and suitable
amounts of bacterial extracts, incubated in buffer giving final
concentrations of lOmM Tris.HCl pH 7.5, lmM EDTA, lOmM
mercaptoethanol, 0.1 % CHAPS and lOOmM NaCl. After a 20
minute incubation at 22°C, MgCl2 ( to lOmM), CaCl2 (to 2mM)
and 0.0625 units of DNase I were added, mixed and incubated
for a further 60 seconds, after which time 20/tg of proteinase
K in 100/tl of a buffer containing 1% SDS, 100/tg/ml tRNA,
200mM NaCl, 20mM EDTA was added and the reaction
incubated at 50°C for a further 20 mins. The DNA was then
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extracted by phenol, chloroform and ethanol precipitation and
resuspended in formamide dye mix (lmg/ml xylene cyanol,
lmg/ml bromophenol blue and lOmM EDTA in deionized
formamide). In addition, a G+A Maxam-Gilbert sequencing
reaction (35) was carried out on 4ng of the particular end-labelled
probe used in each DNase I footprinting experiment to provide
a sequencing ladder for orientation of the footprint. Samples were
applied to 8% polyacrylamide/8M urea sequencing gels for BT
and UP6 probes and 12% polyacrylamide/8M urea gels for the
shorter HSV-1IE-3 Aval-BamHI probe, and electrophoresed at
40W for 2 - 3 hrs. as required. Gels were dried prior to
visualization of DNase I protection patterns by autoradiography.
RESULTS
Cloning and expression of the DNA binding domain of 140k
in a T7 expression vector and its subsequent partial
purification
Gene 62, encoding the 140k protein, lies in the left repeat
bounding the short unique segment of the VZV genome
(Figure 1); an identical copy (gene 71) lies in the opposite
orientation in the terminal short repeat. The DNA binding domain
of the homologous protein of HSV-1, Vmwl75, has been
ORF62 ORF71
1310 aa
! region 2
(Smaiy(B»tEir)
BamHI
(Hndlll)
(EcoRI)
VZV
140K
VT2
Sphl/(Pvull)
Figure 1. A. The structure of the VZV genome with the repeated sequ > shown
as boxes and the positions of the ORF 62 and ORF 71 marked in the short repeats.
B. Expansion of the 140k coding region (1310 amino acid residues in length).
C. The location of the region of 140k encompassing hs DNA binding domain,
this VT2 region includes 51 residues from the C-terminal portion of non-conserved
region 1, the whole of region 2 (codons 468—641) and 5 residues from region
3. D. The 140k DNA binding domain inserted into the T7 expression vector
p585T7a to give plasmid p585T7aVT2. Only positions of restriction sites altered
during the construction of the p585T7a vector and also shes relevant to the
subcloning of the 140k VT2 region are indicated. The location of the T7
transcriptkmal initiation and termination signals are marked by open boxes
containing arrows to indicate the direction of expression. The Mack box represents
the NcoI-EcoRI oligonucleotide adaptor inserted to maintain the 140k reading
frame and to facilitate the insertion of the EcoRI-BstEE gene 62 fragment from
plasmid pV17 into the vector p585T7a. The shaded box represents the 140k coding
region (codons 417—646).
expressed in isolation and found to have a similar binding
specificity to that of the intact protein (21,25,31). Our intention
was to express the equivalent region of the homologous VZV
IE protein 140k, encompassing its DNA binding domain, in order
to study its DNA binding characteristics for comparison with
those of the HSV-1 Vmwl75 DNA binding domain. Wu and
Wilcox (27) had previously expressed in E.coli the 140k codons
417 to 647, proceeded by 323 codons derived from the trpE ORF,
and had found that this fusion pepti.de bound DNA in a sequence-
specific manner. We chose to express a similar region of 140k
as a non-fusion polypeptide to eliminate the possible influence
of a large stretch of non-homologous E.coli coding region on
the properties of the fusion protein. Our non-fusion polypeptide
spanned VZV 140k codons 417 to 646 and mainly consisted of
the highly conserved region 2, designated on the basis of
homology between the HSV-1 Vmwl75 and the VZV 140k
proteins (18). The C-terminal portion of region 1, poorly
conserved in the related IE proteins of the a-herpesviruses, was
also included in our expressed peptide; the role played by these
additional residues is not fully understood but deletion analysis
on the 140k DNA binding domain found them to be necessary
for the production of a clear DNase I footprint but not for binding
in gel retardation assays (see below).
The DNA binding domain of 140k was cloned into the T7
expression vector p585T7a, as described in detail in the materials
and methods section. The resulting plasmids p585T7aVT2 and
p585T7aVT2X both contained the gene 62 coding region for 140k
residues 417—646 inclusive, differing from each other only by
the extent of vector coding sequences to the 3' of this gene 62
region. The expressed polypeptides will be referred to as VT2
and VT2X respectively. Both of these 140k DNA binding domain
peptides were expressed to high levels and were clearly visible
on SDS-PAGE gels stained with Coomassie blue (Figure 2). The
VT2X version of VT2 was constructed due to the finding that
BL21 VT2 VT2X
"IMW
kD
— 66
—• 45
— 36
• *» 24
" -«• 20.1
14.2
1 2 3 4 5 6 7 8 9 10
Figure 2. Expression of the 140k DNA binding domain in E.coli. Bacteria were
grown, expression from the T7 plasmids induced and crude extracts were prepared
by ammonium sulphate precipitation and analyzed on 12.5% SDS PAGE. BL21
is an extract prepared from induced bacteria without an expression plasmid, VT2
and VT2X indicate extracts prepared from bacteria carrying plasmids p585T7aVT2
and p585T7aVT2X respectively. Lanes 1,4,7—lysed bacteria after harvesting;
lanes 2,5,8—post polymin P precipitation supematants; lanes 3,6,9—crude extracts
after 35% ammonium sulphate precipitation. The amount of extract in each lane
corresponds to diat produced from 3ml of induced bacterial culture. Lane
10-molecular weight standards; BSA, 66kD; albumin, 45kD;
glutataldehyde-3-phosphate dehydrogenase, 35kD; trypsinogen, 24kD; trypsin
inhibitor, 20.1kD; lactalbumin, 14.2 kD. The positions of VT2 (28.5kD) and
VT2X (26.4kD) peptides are marked by arrows.
 at U
niversity of G
lasgow
 on D
ecem
ber 19, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 1993, Vol. 21, No. 3 517
'X' versions of the HSV-1 Vmwl75 DNA binding domain
peptides were generally more stable than the non-X versions (31).
The VT2X polypepti.de was expressed at slightly higher levels
and had an increased DNA binding affinity as compared to the
VT2 version (data not shown); otherwise these two proteins could
be considered identical. Partially purified extracts of bacterially
expressed VT2 and VT2X were obtained by ammonium sulphate
precipitation (Figure 2) and were used for all subsequent DNA
binding analyses.
The 140k DNA binding domain specifically recognizes
multiple gene 62 promoter sequences in DNase I footprinting
assays
Initial experiments using the VT2X peptide with the UP6 probe
(described in materials and methods) indicated the formation of
defined DNA:protein complexes. With increasing amounts of
protein, higher order complexes containing more than one VT2X
peptide were observed (results not shown, but see Figure 5).
We investigated the interaction of VT2 on a number of different
probes by DNase I footprinting. Typical results (Figure 4)
indicated that VT2 bound (with apparently similar affinity) to
several sites within the gene 62 promoter region (summarized
in Figure 3), and that many of these sites contained sequences
similar to the HSV-1 Vmwl75 binding site consensus (Figure 3).
VZV ORF 62 Promoter:
-apo -200 -100 +1 +100
Falser (-287) McKee(+1)
-306
TATA
-255
TAATGAAAT
-28
TATA
ATCQTCTQTHQACACACntTOAT
/fl/|/A\
-' ACOOTQACG-' • AldCAATCCTTT
P2 ! :7P4
b
P2 !
»TCQTCTTATC O
P5
\
iCTC
OTCOAQ
P3
DNA probes:
UP6 fragment: BT fragment:
-409 -130 +57
UP6 oligo:
I 1
-311 -283
Characteristically these sites were flanked by regions of DNase
I hypersensitivity (Figure 4).
The 140k DNA binding domain recognizes the HSV-1 IE-3
promoter Vmwl75 binding site in gel retardation and
footprinting analyses
Several of the VT2 binding sites, as identified by the DNase I
footprinting analysis on the gene 62 promoter, showed sequence
homology to the HSV-1 Vmwl75 DNA binding consensus AT-
CGTnnnnnYSG (21). This had been noted previously (27) but
in view of the observation that VZV 140k did not repress the
HSV-1 promoter (17) we decided to investigate the relationship
P1
-409
12345678 9 12345678
Figure 3 . Schematic diagram of the gene 62 promoter region. Numbers on the
top scale indicate nucleotide positions corresponding to the gene 62 promoter.
The locations of both proposed mRNA start sites are shown by bent arrows. A
TATA box homology TTTTAA is centered at nucleotide - 2 8 . A sequence at
- 2 6 1 to - 2 4 9 contains both octamer and TAATGARAT motifs (28). The
proposed start site at - 2 8 7 also has a TATA box homology (TATAT) centered
at nucleotide - 3 0 6 . Expansions of the gene 62 promoter sequences (coding strand)
specifically protected from DNase I digestion by the 140k DNA binding domain
peptide VT2 are also given. These sequences are labelled U, PI to P5 and obvious
homologies to the motif found in the 5' portion of the HSV-1 Vmwl75 binding
consensus are underlined, the arrow inHiratrng a motif in the opposite orientation
on die non-coding strand. The bottom section shows die relative positions of the
probe fragments derived from the gene 62 promoter and die restriction sites used
for their isolation. In the case of the UP6 oligo, the numbers refer to the region
of the gene 62 promoter included in the oligonucleotide probe sequence.
Figure 4. DNase I footprints on the VZV gene 62 promoter. DNase I footprinting
assays were performed with 5' end-labelled DNA fragments and bacterial extracts.
Target DNAs derived from the gene 62 promoter region were (A) UP6 fragment
(bp - 4 0 9 to - 1 8 8 ) and (B) BT fragment (bp - 1 2 0 to +57) , in both cases die
non-coding strand was labelled. Arrows indicate die proposed transcriptional
initiation sites at nucleotide - 2 8 7 in (A) and at + 1 in (B). Brackets representing
regions of protection from DNase I digestion are labelled U ( - 3 0 2 to - 2 8 0 ) ,
P l ( - 1 0 7 to - 9 7 ) , P2 ( - 8 1 to - 7 4 ) , P3 ( - 5 2 to - 4 7 ) , P4 ( + 6 to +18) and
P5 ( + 2 7 to +46) . Tracks labelled G + A , - a n d con contain Maxam and Gilbert
sequencing reaction, no extract and J~<"^H bacterial extract carrying the p585T7a
vector respectively. Tracks labelled VT2 contain bacterial VT2 extract Triangles
represent progressively increasing amounts of extract in die lanes covered by the
triangle, die amounts of control extract corresponding to the same range of amounts
of the VT2 extract used.
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Figure 5. A. Gel retardation analysis of HSV-1 IE-3 and VZV gene 62 promoter
regions. Target DNAs; lanes 1 - 5 contain HSV-1 IE-3 promoter EcoRI-BamHI
fragment probe (-108 to +27), lanes 6-10 contain UP6oligo probe including
gene 62 promoter sequences from -311 to -283 , lanes 11-15 contain the gene
62 promoter Xhol-Bgin fragment BT probe (-130 to +57). These target DNAs
were incubated with approximately equivalent amounts of VZV VT2X or HSV-1
I9X bacterial extracts, or equivalent amounts of HeLa nuclear extracts with or
without intact Vmwl75. Prokmged autoradiographic exposure of the gd (as shown
here) was necessary to visualize the complex between the HSV-1 IE-3 promoter
and intact Vmwl75 (lane 5) marked by an arrow to the left hand side of panel
A. Panels B. and C. show DNase I footprinting analyses of the HSV-1 IE-3
promoter Aval-BamHI fragment ( -18 to +27), but only nudeotides - 1 5 to +15
are shown. In both panels; lane 1 contains a G+A Maxam and Gilbert sequencing
reaction and lane 2 contains no extract. In B.; lane 3 contains an extract from
bacteria containing plasmid p585T7a; lanes 4 - 8 contain increasing amounts of
bacterial VZV VT2 extract. In C ; lanes 3 - 5 contain increasing amounts of
bacteria] HSV-119X extract An expansion of the sequence of the IE-3 promoter
Vmwl75 consensus binding site is shown and the direction and position of
transcription initiation is marked by the arrow.
between VT2 and Vmwl75 binding sites in detail. Firstly we
confirmed that the VZV DNA binding domain could interact with
the Vmwl75 binding site in the IE-3 promoter. Incubation of
the VT2X peptide with an IE-3 probe (coordinates -108 to +27)
gave specific proteur.DNA complexes (Figure 5A, lane 2) and
again additional multiple complexes arose on titration of the
VT2X peptide (data not shown) as noted earlier with the gene
62 promoter probes. Lesser exposures of the gel in Figure 5A
show three such multiple VT2X complexes on the IE-3 probe
(lane 2).
A high-resolution DNase I footprinting analysis on the Aval-
BamHI HSV-1 IE-3 fragment probe ( -18 to +27) provided
verification that the 140k DNA binding domain specifically
recognized the HSV-1 IE-3 Vmwl75 consensus binding site. The
VT2 peptide protected, albeit faintly, both halves of this bipartite
Vmwl75 consensus site (21) from DNase I digestion (Figure 5B).
DNase I hypersensitivity was again induced at the edges of the
protected sequences as the amount of VT2 extract present
increased. The footprint produced at this site by the VZV 140k
VT2 DNA binding domain differed in several respects to that
produced by protein I9X, the corresponding domain of Vmwl75
(Figure 5C). VT2 induced greater DNase I hypersensitivity at
the 5' side of the binding site but less complete protection within
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Figure 6. Comparison of the effect of point mutations in the HSV-1 IE-3 consensus
binding site on the binding efficiencies of I9X and VT2. The sequence in the
region of the IE-3 Vmwl75 binding site is shown in large type at OK bottom
of both panels. The vertical bars above each base represent the percentage efficiency
of binding when that base was mutated to the one shown in smaller type below
(compared to binding efficiency to the wild type probe). Data used to produce
die KX binding profile was abstracted from reference 21. Analysis of VT2 binding
efficiency was carried out with sets of mutagenized probe fragments produced
on two separate occasions and gave highly reproducible results. Values used to
produce the VT2 binding profile represent averages of the results provided by
these two analyses.
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the binding site itself. Strikingly VT2 induced hypersensitivity
in the central section of the binding site while I9X completely
protected diis region. Therefore although both proteins bind to
the same site, the details of their structural interactions must
differ.
The 140k DNA binding domain exhibits reduced binding
specificity for an HSV-1 Vmwl75 consensus binding site, as
compared to the corresponding domain of Vmwl75
Having established that the 140k DNA binding domain recognized
the HSV-1 IE-3 promoter binding site, we decided to compare
the binding specificities of the HSV-1 Vmwl75 and VZV 140k
proteins. Our intention was to identify differences in die binding
specificities of diese two homologous IE proteins that might
account for their opposing functional effects on the EE-3 promoter
seen in transfection assays (17). An extensive mutagenesis of die
IE-3 binding site had been performed previously for an analysis
of die sequence requirements for Vmwl75 binding (21). We
utilized the progeny M13 phage resulting from this study to isolate
'prime cut' Aval-BamHI IE-3 fragment ( -18 to +27) probes,
containing single point mutations at all positions throughout this
IE-3 consensus binding site. The probes were used in gel
retardation experiments widi the VT2 bacterial extract to
determine die VT2 binding specificity for die IE-3 binding site.
The percentage efficiency of VT2 binding to each mutant probe
was determined widi respect to binding to die wild-type probe.
The results are summarized in histogram form in the bottom
section of Figure 6 widi die previously determined binding profile
for the Vmwl75 DNA binding domain peptide I9X (21,31)
shown above. It is apparent diat die 140k DNA binding domain
has an overall reduced binding specificity for diis IE-3 consensus
binding site compared to diat of die Vmwl75 DNA binding
domain and appears to be virtually insensitive to point mutations
in me 3' portion of die bipartite sequence.
Both intact HSV-1 Vmwl75 and its isolated DNA binding
domain have very low affinities for the VZV gene 62 promoter
VT2 binding sites
We had demonstrated diat die 140k DNA binding domain
specifically recognized die HSV-1 IE-3 promoter binding site and
were interested to determine whedier die HSV-1 Vmwl75 DNA
binding domain would interact widi die 140k binding sites
identified in die VZV gene 62 promoter. Approximately
equivalent amounts of VT2X and die corresponding Vmwl75
DNA binding domain peptide I9X (31) were incubated widi IE-3
promoter and gene 62 promoter probes and die resultant
complexes analyzed by gel retardation assays. We found diat
complexes specific to I9X were undetectable widi die UP6 oligo
probe (Figure 5A, lane 8) which spans die gene 62 promoter U
site (strongly protected by VT2 in DNase I footprinting). I9X
incubation widi die BT probe, which includes die 140k binding
sites P1-P5 , also gave no obvious specific complexes
(Figure 5A, lane 13). On repetition of diis analysis widi greater
amounts of I9X extract, faint protein.DNA complexes were
detected widi die gene 62 promoter BT probe (data not shown).
To verify diat die binding results obtained for I9X reflect die
situation widi intact Vmwl75, nuclear extracts from HeLa cells,
transfected eimer widi or widiout plasmid pi75 (30) were also
incubated with die same probes as above. The only protein:DNA
complex specific to intact Vmwl75 produced in diis gel
retardation analysis was widi die HSV-1 IE-3 probe (seen in lane
5 of Figure 5A, marked by die horizontal arrow), die complexes
obtained widi die UP6 oligo and BT gene 62 promoter probes
being identical for nuclear extracts widi or widiout Vmwl75
(Figure 5A, lanes 10 and 9, 15 and 14 respectively). We conclude
diat intact HSV-1 Vmwl75 and its isolated DNA binding domain
botii have greatly reduced affinities for die VT2 binding sites
in die VZV gene 62 promoter, compared to die binding observed
widi die VZV 140k DNA binding domain. So aldiough several
of die VT2 binding sites in die gene 62 promoter show sequence
similarity to die Vmwl75 binding consensus, die degree of
homology of die sites is insufficient to allow recognition of uiese
gene 62 promoter sites by die comparatively specific Vmwl75
protein. These results are in agreement widi diose obtained from
die above specificity comparison between VZV VT2 and HSV-1
I9X DNA binding domain peptides, which found VT2 to be
generally less sequence-specific than die Vmwl75 DNA binding
domain. In addition, HSV-1 I9X protection of die strong VT2
binding site U in die VZV gene 62 promoter was undetectable
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Figure 7. The circular permutation gel retardation assay with the VT2 peptide.
A. Circular permutation gel retardation assay with the gene 62 promoter U and
P4/P5 binding sites. Lane 1 contains free probe while lane 8 contains probe derived
from the plasmid pBEND2 by BamHI digestion. Probes in lanes 1,2,3 and 4
(which include site U) were derived from the plasmid pBENDU by cutting with
the relevant enzymes indicated above each lane. Similarly for probes in lanes
5,6 and 7 (which include sites P4 and P5) were derived from plasmid pBENDP.
Incubation mixes for lanes 2 - 8 contained sufficient VT2 extract to produce only
primary complexes and the amount of non-specific inhibitor (polydI:polydQ was
increased to 4/ig per reaction to reduce the extent of non-specific VT2 binding
to the non-gene 62 promoter derived probe regions. Non-specific DNA binding
still occurred, represented by the faint complex seen in lane 8 containing the
pBEND2 probe with no introduced VT2 binding site, but this non-specific binding
complex is a minor species compared to the specific primary complexes apparent
in lanes 2 - 7 . B. Schematic showing a binding site containing fragment (depicted
by the box) inserted between the pBEND2 derived tandemly repeated sequence.
Bgin, Xhol and BamHI restriction sites are at equivalent positions in each of
the repeats as shown. Single enzyme digestions yield fragments of identical lengths
but with the position of the binding site circularly permuted with respect to the
ends of the probes.
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Figure 8. A. Schematic diagram of the deletion constructs of the VZV 140k DNA binding domain. The expressed regions of the 140k protein (labelled VT1 - VT5,
VT7 and VT11) are indicated by horizontal lines. The numbers of the 140k residues at the amino- and carboxy-terminal ends of each deletion polypcptide are given
and the corresponding restriction sites used for the isolation and cloning of gene 62 sequences into the T7 expression vectors are shown above. The gene 62 fragment
used in the construction of the plasmid expressing VT5 was isolated from plasmid pV18 (39) which is a derivative of pl40 (28) with a 12bp EcoRI linker oligonucleotide
inserted at codon 472. The remaining gene 62 fragments were all isolated from plasmid pV17 (refer to materials and methods). The ability of each deletion polypeptide
to bind to DNA (+) or not ( - ) in gel retardation analyses is summarized on the right hand side of panel A. B. Gel retardation experiment with the 140k DNA
binding domain deletion polypeptides. Partially purified bacterial extracts of each deletion polypeptide were incubated with tne HSV-1 IE3 promoter Aval-BamHI
fragment probe and resultant complexes analyzed by electrophoresis. Similar results were obtained with VZV gene 62 promoter fragment probes. The particular
deletion polypeptide extract present in each incubation is indicated for lanes 2 - 8 , BL21 indicates an extract from bacteria carrying plasmid p585T7a.
using DNase I footprinting analysis of the UP6 fragment probe
(data not shown).
Binding of the 140k DNA binding domain does not induce
DNA bending at its gene 62 promoter binding sites
The isolated DNA binding domain of HSV-1 Vmwl75 causes
a significant DNA bend in the immediate vicinity of the Vmwl75
binding sequence spanning the HSV-1 IE-3 mRNA start she (26).
This may play a role in the autoregulatory function of Vmwl75.
Since we had found that the 140k DNA binding domain
recognizes sites bearing similarity to the Vmwl75 consensus
binding sequence, and moreover, specifically recognizes this IE-3
promoter binding site, it was of interest to determine whether
VT2 binding would induce a similar conformational change on
the DNA at its binding sites in the vicinities of both proposed
gene 62 mRNA start sites. The method used to detect DNA
bending depends on the principle that a bend near the end of a
restriction fragment causes a less pronounced reduction in
electrophoretic mobility as compared to a bend in the middle.
In order to test for VT2 induced DNA bending, we cloned regions
of the gene 62 promoter, spanning the U site and also the P4/P5
140k binding sites (identified by the DNase I footprinting analysis)
into the pBEND2 plasmid (33). Probe fragments derived from
the resultant pBENDU and pBENDP plasmids, by cutting with
either BgUI, Xhol or BamHI, contained respectively a single or
pair of VT2 binding sites at circularly permuted positions within
each set of three probes (Figure 7B). The VT2 DNA binding
domain peptide VT2 was incubated with each of the probes and
the resulting complexes separated on polyacrylamide gels. An
example of a typical bending analysis is shown in Figure 7A;
there is no significant difference in mobility of the primary
protein:DNA complex within each set of three probes derived
from either the pBENDU or pBENDP plasmids. Thus the 140k
DNA binding domain does not appear to induce DNA bending
at the VT2 binding sites in the vicinities of the proposed gene
62 mRNA start sites.
The DNA binding activity of VZV 140k resides within residues
472 to 633 as determined by gel retardation analysis
VZV 140k DNA binding domain deletion polypeptides were
expressed to high levels in E.coli and partially purified as
described for the VT2 polypeptide. Details of the expressed
regions are given in Figure 8A. The DNA binding ability of each
deletion polypeptide was assayed by gel retardation analysis, an
example of which is shown in Figure 8B. Polypeptides VT1 to
VT5 gave well defined protein:DNA complexes while VT7
(residues 472 - 594) and VT11 (residues 504 - 646) failed to bind
to the DNA probe (Figure 8B, lanes 7 and 8 respectively) even
at greatly increased protein concentrations (data not shown). From
this deletion analysis we conclude that the minimal DNA binding
domain of the 140k protein lies within residues 472 to 633. The
VT2 peptide was selected for all of the above DNA binding
analyses for several reasons. The longer VT1 peptide was less
stable than VT2 and tended to degrade in the bacterial extracts.
The shorter peptides VT4 and VT5 gave good DNA binding in
gel retardation assays, but, for reasons unknown, failed to yield
DNase I footprints at the VT2 binding sites described above.
Despite this lack of footprinting, the specificity of binding of the
shorter VT4 peptide was very similar to that shown in Figure 6B
using VT2 (data not shown). Although the VT3 peptide bound
to DNA in both types of assays, it is interesting that the mobility
of the VT3 complex is greater than expected (Figure 8B, lane
4). It is possible that the deletion is encroaching upon an important
part of the protein and altering the conformation of the complex.
DISCUSSION
The results in this paper demonstrate that a portion of the VZV
140k protein comprising the C-terminal portion of region 1 and
all of the conserved region 2 can be expressed in isolation in
E. coli as a non-fusion DNA binding domain peptide that interacts
with multiple sequences in the VZV gene 62 promoter. Several
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of these sequences are similar to the HSV-1 Vmwl75 binding
consensus, although numerous differences in binding
characteristics between the homologous VZV 140k and HSV-1
Vmwl75 DNA binding domain peptides have been identified.
The possible functional implications of these observations are
considered below.
We chose to utilize the isolated DNA binding domain of the
VZV 140k protein for these analyses due to the difficulties
encountered in a previous attempt to detect sequence-specific
DNA binding by the intact 140k polypeptide (39). The sequence-
specific DNA binding function of HSV-1 Vmwl75 resides in
a discrete domain of the polypeptide comprising mainly the highly
conserved region 2 sequences. This Vmwl75 domain, when
expressed in bacteria or liberated from the intact protein by
proteolytic cleavage, is able to bind DNA with a very similar
affinity and specificity to the intact polypeptide (25,21,24).
Therefore it is reasonable to assume that the binding properties
of the 140k DNA binding domain presented here reflect those
of the full 140k polypeptide.
Autoregulation of the HSV-1 IE-3 gene requires (at least in
transfection assays) interaction of Vmwl75 with a specific binding
site in the IE-3 promoter (36). Similarly the 140k DNA binding
domain specifically recognizes its own gene 62 promoter and by
analogy to the situation with Vmwl75, this interaction is
implicated in the autoregulatory function of 140k. The ability
to bind multiple sites in the gene 62 promoter had been recognized
previously by Wu and Wilcox (27) using a 140k region 2 domain
fusion protein; our analyses utilizing a non-fusion 140k DNA
binding domain polypeptide (VT2) confirm and extend this
observation. The VT2 peptide exhibits slightly differing affinities
for the numerous binding sites in the gene 62 promoter, but
preferential binding to any single site was not apparent.
Binding to multiple sites is unlikely to be a feature specific
to the autoregulatory function of 140k, since DNase I footprinting
analysis of the HSV-1 glycoprotein gD promoter, which is
activated by 140k in transfection assays (15), identifies multiple
sites of VT2 protection and extensive DNase I hypersensitivity
(data not shown). In addition, the homologous IE protein of PRV
(IE 180) binds multiple sequences with limited homology in the
AdML and hsp70 promoters and such binding is necessary for
the activation of these promoters by the PRV IE 180 protein (37).
No obvious 140k binding consensus could be derived from the
gene 62 promoter binding sites, although several of the more
strongly protected sequences contain homologies to the 5' portion
of the Vmwl75 binding consensus (21, 22). Interestingly two
such sites are located in the immediate vicinities of both the
transcription initiation site at +1 and the proposed transcription
initiation site further upstream at —287. A thorough mutational
analysis of the gene 62 promoter would be necessary to determine
whether these, or any other specific binding sites, are required
for the downregulation of this promoter by the 140k protein.
Our examination of the specificity of VT2 for a Vmwl75
consensus binding site found that sequences in the 3' portion of
the consensus site were unimportant for VT2 binding. It is
possible that the VT2 binding sites may have their own distinct
3' sequence, but none is apparent for die sites identified in this
study. The results presented here show the 140k DNA binding
domain has a lower DNA binding specificity compared to the
equivalent domain of Vmwl75. This is reflected in the high
number and the variety of the sequences protected by VT2 in
the gene 62 (Figure 3) and HSV-1 gD promoters and also the
high level of non-specific binding to the pBEND2 probe
(Figure 7A, lane 8). This low specificity of DNA binding might
perhaps explain the promiscuous transactivating phenotype of
140k in transfection assays (15,16). It can be predicted from the
low binding specificity of the 140k DNA binding domain, that
the intact 140k protein would have a low promoter selectivity;
140k could perhaps function by activating sub-optimally utilized
RNA polymerase II promoters in a similar manner to that
previously suggested for the homologous PRV IE 180 protein
(38). The 140k protein is also a more potent transactivator than
Vmwl75 in transfection assays (15,16). This is not merely a
function of the relative strengths of the HSV-1 IE-3 and VZV
gene 62 promoters (39) but could be attributable to either the
relative strengths of their activating domains (unknown at present)
or alternatively multiple 140k interactions with the promoter may
have an additive effect, enhancing the efficiency of activation.
Our results suggest that DNA binding to a sequence over the
transcription initiation site is not sufficient for autoregulation as
protein VT2 specifically interacts with the HSV-1 IE-3 consensus
site yet evidence from transfection assays (17) and also the
recombinant HSV-140 virus (13) suggests that intact 140k fails
to repress this IE-3 promoter. In addition, although Vmwl75 is
equally as effective as 140k in the downregulation of the gene
62 promoter in transfection assays (17), intact Vmwl75 and also
its isolated DNA binding domain displayed greatly reduced
affinities for the binding sites therein, compared to the 140k DNA
binding domain. Slight differences between the sequences of the
specific binding sites found in the region of the IE-3 and gene
62 mRNA start sites may account for this functional
inconsistency. Alternatively the precise positioning of the IE-3
site with respect to the mRNA start site may not be correct for
downregulation of this promoter by the 140k protein, as a close
correlation has been observed between Vmwl75 mediated
autorepression and the stereo-specific or distance-dependent
placement of the IE-3 binding site and die TATA box (discussion
of reference 40). It seems that the mechanism of autoregulation
of the gene 62 promoter is more complicated than DNA binding
alone and is likely to involve interactions with other proteins.
Of possible functional significance are the alterations of DNA
conformation induced by binding of the VT2 peptide, made
apparent by the strong sites of DNase I hypersensitivity in the
gene 62 promoter (Figure 4). The purified DNA binding domain
of Vmwl75 significantly bends the DNA at its binding sites (26),
whereas VT2 induced bending was not detected in a
corresponding analysis. This lack of DNA bending at individual
VT2 binding sites and also the extensive nature of the
hypersensitivity pattern suggest mat the conformational effects
may extend along the whole promoter, induced by multiple VT2
peptides binding to numerous sites. If this transpires to be the
case for binding of the intact 140k protein during VZV infection,
numerous possible functional implications of such a broad-ranging
conformational effect can be envisaged, including modification
of the interactions of transcription factors with DNA or with other
proteins, or clearing the promoter of non-specific DNA binding
proteins.
Despite the equivalent roles played by the HSV-1 Vmwl75
and VZV 140k proteins in dieir respective viruses and the high
level of sequence homology between their DNA binding domains,
numerous differences in their DNA binding characteristics are
apparent and are likely to have an important bearing on their
activities during infection.
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